Spots Global Cancer Trial Database for varlilumab
Every month we try and update this database with for varlilumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | NCT02302339 | Melanoma | glembatumumab v... glembatumumab v... glembatumumab v... glembatumumab v... | 18 Years - | Celldex Therapeutics | |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | NCT02924038 | Glioma Malignant Gliom... Astrocytoma, Gr... Oligodendroglio... Glioma, Astrocy... Oligoastrocytom... | IMA950 poly-ICLC Varlilumab | 18 Years - | University of California, San Francisco | |
| DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab | NCT03688178 | Glioblastoma | Human CMV pp65-... Temozolomide Varlilumab Td Unpulsed DCs | 18 Years - | Duke University | |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | NCT04941287 | Metastatic Dist... Metastatic Gall... Metastatic Intr... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage IV Distal... Stage IV Gallbl... Stage IV Intrah... Unresectable Li... | Atezolizumab Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Magnetic Resona... Varlilumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | NCT02924038 | Glioma Malignant Gliom... Astrocytoma, Gr... Oligodendroglio... Glioma, Astrocy... Oligoastrocytom... | IMA950 poly-ICLC Varlilumab | 18 Years - | University of California, San Francisco | |
| A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma | NCT03307746 | B Cell Lymphoma | Varlilumab | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | NCT03617328 | Melanoma | 6MHP Montanide ISA-5... polyICLC CDX-1127 | 18 Years - | University of Virginia | |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | NCT02924038 | Glioma Malignant Gliom... Astrocytoma, Gr... Oligodendroglio... Glioma, Astrocy... Oligoastrocytom... | IMA950 poly-ICLC Varlilumab | 18 Years - | University of California, San Francisco | |
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | NCT02302339 | Melanoma | glembatumumab v... glembatumumab v... glembatumumab v... glembatumumab v... | 18 Years - | Celldex Therapeutics | |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | NCT04941287 | Metastatic Dist... Metastatic Gall... Metastatic Intr... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage IV Distal... Stage IV Gallbl... Stage IV Intrah... Unresectable Li... | Atezolizumab Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Magnetic Resona... Varlilumab | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
